Pfizer shoots itself on Wall Street by the possible vaccine

The vaccine to counteract the COVID-19 It is the most precious booty by all pharmaceutical companies at this time. In that race for health, Pfizer seems to have taken advantage. Its shares closed the session with an increase of 3.21% in Wall street after reporting positive results in the first tests with his vaccine.

The tests, carried out by the German BioNTech laboratory, were carried out on 45 adults between 18 and 55 years old. Different doses of the vaccine were tested that produced antibodies higher than those of patients who have recovered from COVID-19. These data will be reviewed by other experts and will be published in a scientific publication.

Kathrin Jansen, Head of Research and Development at Pfizer vaccines, He indicated in a statement that the clinical data is positive and that the work is being carried out with the utmost urgency. He adds that the vaccine was generally well tolerated, although in some cases it caused fevers and local pain where it was injected, but without any serious reaction being detected, according to the EFE agency.

The next step is to use the information collected to make a much broader test, with up to 30 thousand participants, towards the end of July. This in case they receive the approval of the regulators.

If the rest of the tests are successful and receive the corresponding approvals, Pfizer and BoiNTech They have announced that they will manufacture up to 100 million doses in the remainder of the year and potentially more than 1.2 billion during 2021.

It should be noted that this is not the only vaccine that is being tested. In other countries, promising results have also been obtained in the first tests with humans. However, the widespread use of any vaccine against COVID-19 has not been approved so far. According to who, the period for which a vaccine can be made available for use at a mass level is at least 12 to 18 months.

Pfizer wants to make up to 20 million doses of Covid-19 vaccines by the end of 2020

Pfizer plans to develop by the end of this year between 10 million and 20 million doses of a vaccine against coronavirus It is developing together with the German firm BioNtech, for its emergency use depending on the results of clinical trials, said an executive of the American pharmaceutical company.

Pfizer, BioNtech and many other companies and scientists are in a global race to develop a vaccine against the virus, as there are currently no approved treatments and therapies in clinical trials have yielded inconclusive results.

Also on Thursday, British pharmaceutical company AstraZeneca said it joined forces with the Oxford University in a Covid-19 vaccine project that is being tested in volunteers.

Many pharmaceutical companies are in the running for the COVID-19 vaccine

Make millions of doses available in just a few months, as Pfizer hopes, would mark an almost unprecedented speed for a new vaccine and would require swift regulatory action even for emergency use.

“Of course we need to wait to see how the vaccine’s efficacy and safety are demonstrated, hopefully in the coming months,” said Nanette Cocero, global director of Pfizer Vaccines, in a video conference organized by the pharmaceutical industry group IFPMA.

“But assuming that is proven, we are looking to accelerate manufacturing fairly quickly to have around 10 million to 20 million doses by the end of this year, which are expected to be used in an emergency-type environment later.”

Other drug manufacturers testing possible vaccines against Covid-19 They include Moderna, Johnson & Johnson and Novavax, as well as smaller projects such as the Inselspital Bern hospital in Switzerland.

Countries risk billions of dollars in projects that may never succeed, amid desperation to find preventive treatment for the virus that has so far killed more than 220,000 people worldwide and is devastating the world. Global economy.

Find out the latest on digital economy, startups, fintech, corporate innovation and blockchain. CLICK HERE